Adcitmer® , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma.
Clara EsnaultV LeblondC MartinA DesgrangesC B BaltusN AubreyZ LakhrifL LajoieL LantierB ClémenceauB SarmaJ SchramaR HoubenDavid SchramaS HesbacherV Gouilleux-GruartY FengD DimitrovS GuyétantP BerthonM C Viaud-MassuardM SamimiA TouzéT KervarrecPublished in: The British journal of dermatology (2021)
Our study suggests that Adcitmer® should be further assessed as a therapeutic option in patients with MCC, as an alternative therapy or combined with immune checkpoint inhibitors.